TrialBritish journal of cancer2023

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.

Nitya Raj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.